13.07.2015 Views

Development of hot-melt extrusion as a novel technique for the ...

Development of hot-melt extrusion as a novel technique for the ...

Development of hot-melt extrusion as a novel technique for the ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

CHAPTER 4: TASTE MASKING OF PARACETAMOL BY HOT MELTEXTRUSION: AN IN VITRO AND IN VIVO EVALUATION1.0 IntroductionThe t<strong>as</strong>te m<strong>as</strong>king <strong>of</strong> bitter APIs is a major challenge especially <strong>for</strong> <strong>the</strong> development<strong>of</strong> orally disintegrating tablets (ODT) in pharmaceutical industry. Several approaches havebeen reported which involve fluidized-bed coating, supercritical fluids and coacervationapproaches where effective t<strong>as</strong>te-m<strong>as</strong>king is achieved by applying polymeric coating layer tocreate a physical barrier around <strong>the</strong> drug [1, 2] . O<strong>the</strong>r alternatives involve <strong>the</strong> use <strong>of</strong>complexing agents (cylcodextrins, ion exchange resins) through <strong>the</strong> <strong>for</strong>mation <strong>of</strong> inclusioncomplexes or resonates [3] . Recently, t<strong>as</strong>te m<strong>as</strong>king approaches have employed t<strong>as</strong>tesuppressants molecules by blocking <strong>the</strong> gap junction channels ad hemichannels and thussuppressing <strong>the</strong> drugs t<strong>as</strong>te [4,5] . However, <strong>the</strong>re is an enormous need <strong>for</strong> more robust, costeffective and e<strong>as</strong>y to scale – up t<strong>as</strong>te m<strong>as</strong>king technologies. HME is a continuous, one stepprocess that h<strong>as</strong> been used <strong>for</strong> <strong>the</strong> development <strong>of</strong> solid dispersions <strong>of</strong> active substances <strong>for</strong>various applications [6, 7] .Hot-<strong>melt</strong> <strong>extrusion</strong> (HME) h<strong>as</strong> been employed <strong>as</strong> a <strong>novel</strong> <strong>technique</strong> <strong>for</strong> <strong>the</strong><strong>for</strong>mulation <strong>of</strong> oral solid dosage <strong>for</strong>ms in pharmaceutical industries in <strong>the</strong> l<strong>as</strong>t decade. It w<strong>as</strong>initially used in food and pl<strong>as</strong>tic industry but h<strong>as</strong> attracted significant interest in <strong>the</strong>pharmaceutical manufacturing <strong>for</strong> <strong>the</strong> development <strong>of</strong> robust <strong>for</strong>mulations. HME can be usedto develop various <strong>for</strong>mulations such <strong>as</strong> sustained rele<strong>as</strong>e matrices [8–11] . It h<strong>as</strong> also beenintroduced <strong>for</strong> t<strong>as</strong>te m<strong>as</strong>king purposes <strong>of</strong> bitter APIs by involving <strong>the</strong> use <strong>of</strong> t<strong>as</strong>te m<strong>as</strong>kingpolymers that create solid dispersions to prevent bitter drugs from coming in contact with <strong>the</strong>patient‘s t<strong>as</strong>te buds [12–15] .T<strong>as</strong>te m<strong>as</strong>king can be achieved through intermolecular <strong>for</strong>ces (e.g. hydrogen bonding)between <strong>the</strong> active substance and <strong>the</strong> polymer matrix by processing oppositely chargedcompounds [1, 2] . In addition, solid dispersions in which <strong>the</strong> drug is molecularly dispersedwithin <strong>the</strong> polymer matrix have shown effectivenes <strong>for</strong> m<strong>as</strong>king <strong>of</strong> <strong>the</strong> drug‘s unple<strong>as</strong>antt<strong>as</strong>te. Successful t<strong>as</strong>te m<strong>as</strong>king requires development <strong>of</strong> HME processing conditions,drug/polymer ratio and selection <strong>of</strong> <strong>the</strong> appropriate <strong>for</strong>mulation components (Hansensolubility parameters). HME can be used <strong>for</strong> <strong>the</strong> development <strong>of</strong> robust <strong>for</strong>mulations withincre<strong>as</strong>ed patient palatability and compliance. T<strong>as</strong>te m<strong>as</strong>king evaluation <strong>of</strong> pharmaceuticaldosage <strong>for</strong>ms is usually carried out by human t<strong>as</strong>te panels (volunteers) and it can be used <strong>for</strong>fur<strong>the</strong>r product optimization. However, <strong>the</strong> t<strong>as</strong>te <strong>as</strong>sessment is subject to <strong>the</strong> individuals64 | P a g e

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!